Trials / Completed
CompletedNCT00597727
A Study of Sublingual Immunotherapy in Peanut-allergic Children
A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- All
- Age
- 1 Year – 11 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.
Detailed description
In spite of increased recognition and understanding of food allergies, food-induced anaphylaxis remains the single most common cause of anaphylaxis seen in hospital emergency departments, accounting for about one third of anaphylaxis cases seen. It is estimated that about 30,000 food-induced anaphylactic events are seen in U.S. emergency departments each year and that about 200 fatal cases occur in the U.S. each year. Either peanuts or tree nuts cause more than 80% of these reactions. No treatments are available and avoidance is the only approved intervention. The goal of this study is to investigate peanut sublingual immunotherapy (SLIT) as a treatment for children with peanut allergy. This study is primarily designed to evaluate the efficacy and safety of peanut SLIT compared to placebo after 12 months. Secondarily, the study is designed to evaluate the efficacy of extended maintenance dosing of peanut SLIT in inducing lasting tolerance after discontinuation of the peanut SLIT. Mechanistic studies will be completed concurrently as exploratory endpoints to understand changes in the allergic immune response related to peanut SLIT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peanut SLIT | Liquid peanut protein drops diluted in glycerin which are dosed under the tongue. |
| DRUG | Placebo SLIT | Liquid glycerin without peanut which are dosed under the tongue. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2008-01-18
- Last updated
- 2018-03-27
- Results posted
- 2017-05-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00597727. Inclusion in this directory is not an endorsement.